A Phase 2, Multicenter, Single-Arm Study of Eribulin Mesylate With Trastuzumab as First-Line Therapy for Locally Recurrent or Metastatic Human Epidermal Growth Factor Receptor Two (HER2) Positive Breast Cancer
Phase of Trial: Phase II
Latest Information Update: 01 Apr 2017
At a glance
- Drugs Eribulin (Primary) ; Trastuzumab
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Sponsors Eisai Inc
- 10 Feb 2017 Status changed from active, no longer recruiting to completed.
- 14 Dec 2013 Results presented at the 36th Annual San Antonio Breast Cancer Symposium.
- 12 Nov 2013 Planned End Date changed from 1 Aug 2013 to 1 Sep 2014 as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History